Nuvectis Pharma, Inc. (NVCT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NVCT SEC filings page.
This page shows Nuvectis Pharma, Inc. (NVCT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The company is still funding a research-heavy operation externally because recurring losses and cash outflows have not yet been offset by reported revenue.
From FY2024 to FY2025, the net loss widened from$19.0M to$26.4M while operating cash flow also weakened. That combination indicates the larger financing inflows are supporting operating needs rather than replacing an internally cash-generative model.
R&D was
Assets expanded from
Financial Health Signals
Nuvectis Pharma, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Nuvectis Pharma, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Nuvectis Pharma, Inc. reported a net loss of $26.4M while operations used $16.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Nuvectis Pharma, Inc. reported -$7.0M in net income in Q2 2026. This represents a decrease of 10.8% from the same quarter a year earlier. Against the prior quarter it is down 16.0%.
Nuvectis Pharma, Inc. earned -$0.30 per diluted share (EPS) in Q2 2026. That is unchanged from the same quarter a year earlier. Against the prior quarter it is down 15.4%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Nuvectis Pharma, Inc. held $22.2M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Nuvectis Pharma, Inc.'s ROE was -77.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 39.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 34.8 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Nuvectis Pharma, Inc. invested $4.7M in research and development in Q2 2026. This represents an increase of 29.6% from the same quarter a year earlier. Against the prior quarter it is up 14.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
NVCT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $4.7M+29.6% | $4.1M+11.6% | N/A | $5.8M+104.8% | $3.6M+22.8% | $3.7M+38.3% | N/A | $2.8M-37.2% |
| SG&A Expenses | $2.5M-15.7% | $2.2M+14.1% | N/A | $2.0M+31.2% | $3.0M+75.4% | $1.9M+8.8% | N/A | $1.5M-7.9% |
| Operating Income | -$7.2M-9.1% | -$6.3M-12.4% | N/A | -$7.8M-78.8% | -$6.6M-42.0% | -$5.6M-26.7% | N/A | -$4.4M+29.2% |
| Net Income | -$7.0M-10.8% | -$6.0M-13.5% | N/A | -$7.5M-79.7% | -$6.3M-43.0% | -$5.3M-27.8% | N/A | -$4.2M+29.4% |
| EPS (Basic) | -$0.300.0% | -$0.26+3.7% | -$0.31+13.9% | -$0.44-83.3% | -$0.30-15.4% | -$0.27-8.0% | -$0.36+12.2% | -$0.24+35.1% |
| EPS (Diluted) | -$0.300.0% | -$0.26+3.7% | -$0.31+13.9% | -$0.44-83.3% | -$0.30-15.4% | -$0.27-8.0% | -$0.36+12.2% | -$0.24+35.1% |
| Diluted Shares (Avg) | 23M+9.9% | 23M+17.4% | N/A | 23M+31.9% | 21M+26.4% | 20M+20.4% | N/A | 17M+7.0% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.
NVCT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $22.4M-17.1% | $25.4M-15.8% | $31.7M+70.4% | $35.6M+105.6% | $27.0M+47.6% | $30.1M+52.9% | $18.6M-3.0% | $17.3M-22.3% |
| Current Assets | $22.4M-17.1% | $25.4M-15.8% | $31.7M+70.4% | $35.6M+105.6% | $27.0M+47.6% | $30.1M+52.9% | $18.6M-3.0% | $17.3M-22.3% |
| Cash & Equivalents | $22.2M-17.3% | $25.1M-15.9% | $31.6M+70.7% | $35.4M+106.4% | $26.8M+47.9% | $29.9M+53.4% | $18.5M-3.1% | $17.2M-22.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $13.3M+31.2% | $11.2M+21.6% | $13.3M+49.5% | $11.6M+83.3% | $10.1M+75.6% | $9.2M+61.5% | $8.9M+27.3% | $6.3M+13.3% |
| Current Liabilities | $13.3M+31.2% | $11.2M+21.6% | $13.3M+49.5% | $11.6M+83.3% | $10.1M+75.6% | $9.2M+61.5% | $8.9M+27.3% | $6.3M+13.3% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Equity | $9.1M-46.2% | $14.2M-32.1% | $18.4M+89.6% | $24.0M+118.5% | $16.9M+34.7% | $21.0M+49.4% | $9.7M-20.4% | $11.0M-34.1% |
| Retained Earnings | -$112.8M-32.8% | -$105.7M-34.6% | -$99.7M-36.1% | -$92.4M-37.9% | -$84.9M-35.1% | -$78.6M-34.5% | -$73.2M-35.0% | -$67.0M-40.7% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
NVCT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.5M-34.6% | -$6.5M-56.0% | -$4.0M-61.2% | -$4.5M-86.9% | -$3.4M-11.5% | -$4.2M+4.2% | -$2.5M+36.0% | -$2.4M+25.9% |
| Stock-Based Compensation | N/A | $1.9M+35.2% | N/A | N/A | N/A | $1.4M+5.6% | N/A | N/A |
| Investing Cash Flow | N/A | $0 | N/A | N/A | N/A | $0 | N/A | N/A |
| Financing Cash Flow | $1.6M+427.4% | $7K-100.0% | $166K-95.7% | $13.1M+802.1% | $296K-82.3% | $15.5M+230.2% | $3.8M+317.6% | $1.5M+107.3% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
NVCT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -77.3%-39.8pp | -42.5%-17.1pp | N/A | -31.1%+6.7pp | -37.5%-2.2pp | -25.4%+4.3pp | N/A | -37.8%-2.5pp |
| Return on Assets | -31.4%-7.9pp | -23.8%-6.1pp | N/A | -21.0%+3.0pp | -23.4%+0.8pp | -17.7%+3.5pp | N/A | -24.0%+2.4pp |
| Current Ratio | 1.68-1.0x | 2.27-1.0x | 2.38+0.3x | 3.07+0.3x | 2.66-0.5x | 3.28-0.2x | 2.09-0.7x | 2.74-1.3x |
| Debt-to-Equity | 1.46+0.9x | 0.79+0.3x | 0.72-0.2x | 0.48-0.1x | 0.60+0.1x | 0.440.0x | 0.92+0.3x | 0.57+0.2x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. NVCT | FY2025 | N/A | -$26.4M | N/A | $689.4M | — |
| Ventyx Biosciences, Inc. VTYX | FY2024 | N/A | -$135.1M | N/A | $1.0B | — |
| Aardvark Therapeutics, Inc. AARD | FY2025 | $5.1M | -$57.6M | N/A | $104.2M | 55/100 |
| Instil Bio, Inc. TIL | FY2025 | N/A | -$71.4M | N/A | $45.7M | — |
| SANGAMO THERAPEUTICS INC SGMO | FY2025 | $39.6M | -$122.9M | N/A | $55.9M | — |
| Actuate Therapeutics, Inc. ACTU | FY2025 | N/A | -$22.2M | N/A | $14.7M | — |
Where Nuvectis Pharma, Inc. Ranks
Frequently Asked Questions
Is Nuvectis Pharma, Inc. profitable?
No, Nuvectis Pharma, Inc. (NVCT) reported a net income of -$26.4M in fiscal year 2025.
What is Nuvectis Pharma, Inc.'s return on equity (ROE)?
Nuvectis Pharma, Inc. (NVCT) has a return on equity of -143.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nuvectis Pharma, Inc.'s operating cash flow?
Nuvectis Pharma, Inc. (NVCT) recorded an outflow of $16.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Nuvectis Pharma, Inc.'s total assets?
Nuvectis Pharma, Inc. (NVCT) had $31.7M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Nuvectis Pharma, Inc. spend on research and development?
Nuvectis Pharma, Inc. (NVCT) invested $18.2M in research and development during fiscal year 2025.
What is Nuvectis Pharma, Inc.'s current ratio?
Nuvectis Pharma, Inc. (NVCT) had a current ratio of 2.38 as of fiscal year 2025, which is generally considered healthy.
What is Nuvectis Pharma, Inc.'s debt-to-equity ratio?
Nuvectis Pharma, Inc. (NVCT) had a debt-to-equity ratio of 0.72 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nuvectis Pharma, Inc.'s return on assets (ROA)?
Nuvectis Pharma, Inc. (NVCT) had a return on assets of -83.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nuvectis Pharma, Inc.'s P/E ratio?
Nuvectis Pharma, Inc. (NVCT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $689.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Nuvectis Pharma, Inc.'s price-to-sales ratio?
Nuvectis Pharma, Inc. (NVCT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $689.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Nuvectis Pharma, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Nuvectis Pharma, Inc. (NVCT) held $31.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $16.0M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Nuvectis Pharma, Inc.'s Piotroski F-Score?
Nuvectis Pharma, Inc. (NVCT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nuvectis Pharma, Inc.'s earnings high quality?
Nuvectis Pharma, Inc. (NVCT) reported a net loss of $26.4M while operations used $16.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.